WORCESTER, Mass., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced the successful completion of its 2009 annual stockholders’ meeting held on July 30, 2009. An aggregate of 127,891,751 shares, representing 67.60% of the outstanding shares, were voted. All proposals put forward for the stockholders’ consideration in the June 18, 2009 notice of meeting and proxy statement in respect of the meeting were passed.
